APPLICANT FACSANLE OF FORM PTO-1446	Sneet 1 of 8		
REV7-ED	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO	SERVAL NO.
	PATENT AND TRADEMARK OFFICE	BBI-6077CP	09/777,554
LIST OF PUBLICATIONS CITED	BY APPLICANT	APPLICANT	
(Use several sheets if ne	ecessary)	Cusack, K. P. et al.	
1	• .	FILING DATE	GROUP
		February 8, 2001	1626

U.S. PATENT DOCUMENTS

PSMMAJE Jujish		DOCUMENT NUMBER	DATE	, i make	CLASS	SUBCLASS	FILING DATE
RS	A1	4,966,849	10/80	Vailee et al.	435	199	IF APPROPRIATE
RS	AZ	5,217,999	06/93	Levitzki et al.	514	613	<u> </u>
RS	A3	5,302,606	04/94	Spada et al.	514	357	
RS	A4	5,330,992	07/94	Eissenstat et al.	514	312	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	Courtie	CLASS	4080.05	TRAKE	ATION
RS	A5	WO 91/15495 A1	10/91	PCT			Yes	MO.
T	A6	WO 92/20642 A1	11/92	PCT				-
	A7	WO 92/21660 A1	12/92	PCT				┼
	A8	WO 94/03427 A1	02/94	PCT				├
Т	A9	WO 94/10202 A1	05/94	РСТ				┼
	A10	WO 94/14808 A1	07/94	РСТ				
\top	A11	EP 566 226 B1	11/95	EPO				1
	A12	WO 97/22596 A1	06/97	PCT			-	_
	A13	WO 97/34876 A1	09/97	PCT	- -	-		├
	A14	WO97/40830 A1	11/97	PCT				├─
	A15	WO 97/40831 A1	11/97	PCT				
V	A18	WO 97/42187 A1	11/97	PCT				
RS	A17	WO 98/07832 A1	02/98	PCT				├

OTHERS (Including Author, Title, Date, Pertinent Pages, Etc.)

'EXA	MINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applican						
Exam		Date Considered /Rei Tsang Shiao/ (05/15/2006)						
RS		Badger et al., "Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function," The Journal of Pharmacology and Experimental Therapeutics, 279:1453-1461 (1996)						
\downarrow	A21	Armstrong, "Treatment of opportunistic fungal infections," Clinical Infectious Diseases, 16:1-7. (1993)						
1	A20	Aplin et al., "In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta," Journal of Neurochemistry, 67:699-707 (1996)						
	A19	Achen et al, "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinase VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flk4)," PNAS USA 95(2): 548-553 (1998)						
RS	A18	Expert Opin. Ther. Pat. 8(4): 475-478 (1998)						

APPLICANT FACSIME OF FORM PTO 1449	U.S. DEPARTMENT OF		Sh Jof 6
· ·	COMMERCE	ATTY DOCKET NO	BERINL NO.
REV 1-50	PATENT AND TRACEMARK OFFICE	BBI-6077CP	09/777,554
LIST OF PUBLICATIONS CITE	D BY APPLICANT	APPLICANT	
(Use several sheets if r		Cusack, K. P. et al.	
		FRUNG DATE	1626
L		February 8, 2001	1026

OTHERS (Including Author, Title, Date, Pertinent Pages, Etc.)

81	OTHERS (Including Author, Title, Date, Pertinent Pages, Etc.)
RS	Baeuerle et et., "Function and activation of NF-kappa B in the immune system," Annual Review Immunology, 12:141-179 (1994)
BZ	Beg et al., "An essential role for NF-kappaB in preventing TNF-alpha-induced cell death," Science, 274:782-784 (1996)
B3	Bolen, "Nonreceptor tyrosine protein kinases," Oncogene 8:2025-2031 (1993)
B4	Borthwick et al., "Inhibition of glycogen synthase kinase-3 by insulin in cultured human skeletal muscle myoblasts," Biochemical & Biophysical Research Communications, 210:738-745 (1995)
85	Brickell, The p60c-src family of protein-tyrosine kinases: structure, regulation, and function, Critical Reviews in Oncogenesis, 3:401-406 (1992)
B6	Brown et al., Regulation of Angiogenesis (ed. L.D. Goldberg and E.M. Rosen), 233-269 (1997)
B7	Buchdunger et al., "Selective Inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class," PNAS USA 92:2258-2262 (1995)
88	Courtneidge, "Protein tyrosine kinases, with emphasis on the Src family," Seminars in Cancer Biology, 5:236-248 (1994)
89	Cowburn, "Peptide recognition by PTB and PDZ domains," Curr. Opin. Struct. Biol, 7(6):835-838 (1997)
810	De Vries et al. "The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor," Science 255:989-991 (1992)
B11	Draetta, "Cdc2 activation: The interplay of cyclin binding and Thr161 phosphorylation," <i>Trends in Cell Biology</i> , 3:287-289 (1993)
B12	Ducommun et al., "cdc2 phosphorylation is required for its interaction with cyclin," EMBO Journa 10:3311-3319 (1991)
813	Fantl et al., "Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways," Cell 69:413-423 (1992)
B14	Ferrara et al. "The vascular endothelial growth factor family of polypeptides," J. Cell. Biochem. 47:211-218 (1991)
815	Ferrara et al., "Vascular endothelial growth factor. Basic biology and clinical implications," in Regulation of Angiogenesis (ed. L. D. Goldberg and E.M. Rosen), 209-232 (1997)
B16	Ferrara et al., "The biology of vascular endothelial growth factor," Endocrine Reviews 18(1): 4-28 (1997)
817	Gautier et al., "Dephosphorylation and activation of Xenopus p34cdc2 protein kinase during the cell cycle," Nature 339:626-629 (1989)
B18	Gilbert, "Horizontal integration and cortical dynamics," Neuron 9:1-13 (1992)
W B19	Girard et al., "Cyclin A is required for the onset of DNA replication in mammalian fibroblasts," Ce. 67:1169-1179 (1991)
xaminer	Date Considered
	/Rei Tsang Shi ao/ (05/15/2006) Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through

APPLICANT FACEWILE OF FORM PTO-1448	WA 200-1-1-1		Sheet 3 of 6	
	U.S. OLPARTHENT OF CONNERCE	ATTY DOCKET NO	SERIAL NO.	
REY7-40	PATENT AND TRADENARY OFFICE	BBI-6077CP	09/777.554	
LIST OF PUBLICATIONS CITE	D BY APPLICANT	APPURANT		
(Use several sheets if r	recessary)	Cusack, K. P. et al.		
	:	FILMS DATE	GROUP1626	
	·	February 8, 2001		

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

		OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)
RS	Ci	Gould et al., *Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis,* Nature, 342:39-45 (1989)
7	C2	His Made S. Training, 3-2,03-43 (1909)
\parallel		He et al., "The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines," Journal of Virology, 71:405-411 (1997)
Ш	CS	Hosoi et al., "Evidence for cdk5 as a major activity phosphorylating tau protein in porcine brain extract," Journal of Biochemistry (Tokyo), 117:741-749 (1995)
\prod	C4	Hunter et al., "Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age," Cell, 79:573-582 (1994)
	C5	Jakeman et al., "Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis," Endocrinology 133: 848-859 (1993)
\prod	Ċ6	Jellinek, et al., "Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor," Biochemistry 33:10450-56 (1994)
\coprod	C7	Kendall et al., "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," Proc. Natl. Acad. Sci 90:10705-09 (1994)
\coprod	C8	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," Nature 362:841-844 (1993)
Ш	C9	Kinsella, et al. "Protein kinase C regulates endothelial cell tube formation on basement membrane matrix, Matrigel," Exp. Cell Res. 199:58-62 (1992)
Ш	C10	Klagsburn et al., "Vascular endothelial growth factor and its receptors," Cytokine & Growth Factor Reviews 7: 259-270 (1996)
Ш	C11	Koch et al., "SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins," Science 252:668-678 (1991)
	C12	Kohn et al., "Cell cycle control and cancer chemotherapy," Journal of Cellular Biochemistry, 54:440-452 (1994)
	C13	Kolch et al., "Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis," Breast Cancer Research and Treatment 36: 139-155 (1996)
	C14	Korpelainen et al., "Signaling angiogenesis and lymphanglogenesis," Curr. Opin. Cell Biol., 10:159-164 (1998)
	C15	Krek et al., 'Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in vertebrates," EMBO Journal, 10:3331-3341 (1991)
Щ	C16	Lees, "Cyclin dependent kinase regulation," Current Opinion in Cell Biology, 7:773-780 (1995)
	C17	Lymboussaki et al, "Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors," Am. J. Pathol. 153(2): 395-403 (1998)
	C18	Maglione et al. "Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14." Oncodene 8:925-31 (1993)
Ц	C18	Mariani, et al., "inhibition of anglogenesis by FCE 26806, a potent tyrosine kinase inhibitor," Proc. Am. Assoc. Cancer Res. 35:2268 (1994)
*L	C20	Matsushime et al., "D-type cyclin-dependent kinase activity in mammalian cells," Molecular & Cellular Biology, 14:2066-2076 (1994)
xami	ner	Date Considered /Rei Tsang Sh ao/ (05/15/2006)
EXAN	MINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applican

1	APPLICANT FACSIMES OF FORM DYOLIAM			Shace = 018
1		U.E. DEPARTMENT OF COMMERCE	ATTY DOCKET NO	SERVAL NO.
Ì	REV 7-40	PATENT AND TRADEMARK OFFICE	BBI-6077CP	09/777,554
I	LIST OF PUBLICATIONS CITE	D BY APPLICANT	APPLICANT	
	(Use several sheets if n	ecssary)	Cusack, K. P. et al.	
			FILMO DATE	1626
			February 6, 2001	

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) Matthews et al., "A receptor tyrosine kinase cDNA isolated from a population of enriched primitive RS hematopoietic cells and exhibiting close genetic linkage to c-kit," PNAS USA, 88:9026-30 (1991) D2 Meyer et al, "A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Fit-1) receptor tyrosine kinases," EMBO J. 18(2):363-374 (1999) Migdal et al, "Neuropilin-1 is a placenta growth factor-2 receptor," J. Biol. Chem. 273 (35): 22272-22278 (1998) Millauer et al., "High affinity VEGF binding and developmental expression suggest Flk-1 as a **D4** major regulator of vasculogenesis and angiogenesis," Cell 72:835-846 (1993) 05 Murray et al., "Cyclin synthesis drives the early embryonic cell cycle," Nature, 339:275-280 (1989) DA Mustonen et al., "Endothelial receptor tyrosine kinases involved in angiogenesis," J. Cell Biol. 129:895-898 (1995) 07 Myers et al., "The preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)quinazolines; inhibitors of p56th and EGF-R tyrosine kinase activity," Bioorg. Med. Chem. Lett. 7:417-420 (1997) Myers et al., "The synthesis and sar of new 4-(N-alkyl-N-phenyl)amino-6,7dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)amino-pyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity." Bioorganic & Medicinal Chemistry Letters, 7:421-424 (1997) DQ Oelrichs et al, "NYK/FLK-1: a putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo." Oncogene 8(1):11-15 (1993) D10 Ogawa et al, "A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF). preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparinbindirg domain," J. Biol. Chem. 273(47): 31273-31282 (1998) Ohtsubo et el., "Cyclin-dependent regulation of G1 in mammallan fibroblasts," Science, 259:1908-1912 (1993) **D12** Osmani et al., "Parallel activation of the NIMA and p34cdc2 cell cycle-regulated protein kinases is required to initiate mitosis in A. nidulans," Cell, 67:283-291 (1991) Osmani et al., "Activation of the nimA protein kinase plays a unique role during mitosis that cannot be bypassed by absence of the bimE checkpoint," EMBO Journal, 10:2669-2679 (1991) D14 Pagano et al., "Cyclin A is required at two points in the human cell cycle," EMBO Journal, 11:961-971 (1992) Park et al., "Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Fit-1 but not to Fik-1/KDR." J. Biol. Chem. 269:25646-54 (1994) D16 Perkins et al., "Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 RS coactivator," Science, 275:523-527 (1997) Examiner Date Considered /Rei Tsang Shiao/ (05/15/2006) *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Constitution and the second			Sheet 2 94 6
APPLICANT FACEMEN OF FORM PTO-1446	U.S. DEPARTIVENT OF COMMERCE	ATTY DOCKEY NO	SEALL NO
REV 7-40	PATENT AND TRADEWARK OFFICE	BBI-6077CP	09/777,554
LIST OF PUBLICATIONS CITE	D BY APPLICANT	APPUCANT	
(Use several sheets if n	recessary)	Cusack, K. P. et al.	
	•	FEING DATE	1626
		February 8, 2001	1020

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

		OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)
RS	E1	Pines, "Cell proliferation and control," Current Opinion in Cell Biology, 4:144-148 (1992)
	E2	Pines, "Cyclins and cyclin-dependent kinases: take your partners," <i>Trends in Biochemical Sciences</i> , 18:195-197 (1993)
	E3	Powis, "Signalling pathways as targets for anticancer drug development," Pharmacology & Therapeutics, 62:57-95 (1994)
	E4	Quelle et al., "Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts," Genes & Development, 7:1559-1571 (1993)
	E5 .	Resnitzky et al., "Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system," Molecular & Cellular Biology, 14:1669-1679 (1994)
	E6	Ristimaki et al, "Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C," J. Biol. Chem. 273(14):8413-8418 (1998)
	E7	Rosenblatt et al., "Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A." Proc. Nat Acad. Sc. USA, 89:2824-2828 (1992)
	E8	Schlessinger et al., "Growth factor signaling by receptor tyrosine kinases," Neuron 9:383-391 (1992)
	E9	Shawver et al., "Receptor tyrosine kinases as targets for inhibition of angiogenesis," Drug Discovery Today, 2:50-63 (1997)
T	E10	Sherr, "Mammalian G1 cyclins," Cell, 73:1059-1085 (1993)
	E11	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely related to the fms family." Oncogene 5:519-524 (1990)
	E12	Shoelson, "SH2 and PTB domain interactions in tyrosine kinase signal transduction," Curr. Opin. Chem. Biol. 1(2): 227-234 (1997)
T	E13	Solomon et al., "Cyclin activation of p34cdc2," Cell, 63:1013-1024 (1990)
	E 14	Solomon et al., "Role of phosphorylation in p34cdc2 activation; identification of an activating kinase," Molecular Biology of the Cell, 3:13-27 (1992)
	E15	Songyang et al., "SH2 domains recognize specific phosphopeptide sequences," Cell 72:767-778 (1993)
	E16	Songyang et al., "Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav," Moi, Cell. Biol. 14:2777-2785 (1994)
	E17	Staunton et al., "The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and Rhinovirus," Cell 61:243-254 (1990)
	E18	Stone et al., "Reversible, p16-mediated cell cycle arrest as protection from chemotherapy," Cancer Research, 56:3199-3202 (1996)
	E19	Takano, et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase," Mol. Bio. Cell 4:358A (1993)
W RS	E20	Tanaka et al., *c-CBL is downstream of c-Src in a signalling pathway necessary for bone resorption,* Nature, 383:528-531 (1996)
Exam	iner	Date Considered /Rei Tsang Shiao/ (05/15/2006)
EXA	MINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applican
_		

			Susat 6 01 6
APPLICANT FACSDRILE OF FORM PTO-1449	U.S. DEPARTMENT OF CONGERCE	ATTY DOCKEY NO	SERVAL NO
RgV 7-40	PATENT AND TRADEMARK OFFICE	BBI-6077CP	09/777,554
LIST OF PUBLICATIONS CITE	ED BY APPLICANT	APPUGANT	
(Use several sheets if	necessary)	Cusack, K. P. et al.	
		FILING DATE	580UP 1626
		February 8, 2001	

OTHERS (Including Author, Title, Date, Pertinent Pages, Etc.) Terman et al., "Identification of a new andothelial cell growth factor receptor tyrosine kinase," RS Oncogene 6:1677-83 (1991) Terman et al., "Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor," Biochem. Biophys. Res. Comm. 187:1579-86 (1992) Ullrich et al., "Signal transduction by receptors with tyrosine kinase activity," Cell 61:203-212 F4 Van Antwerp et al., "Suppression of TNF-alpha-induced apoptosis by NF-kappaB," Science. 274:787-789 (1996) F5 Vousden, "Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes," FASEB Journal, 7:872-879 (1993) F6 Walker et al., "Role for cyclin A in the dependence of mitosis on completion of DNA replication," Nature, 354:314-317 (1991) Wang et al., "TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NFkappaB, Science, 274:784-787 (1996) Williams, "Factors regulating the expression of vascular permeability/vascular endothelial growth factor by human vascular tissues, Diabetelogia 40: S118-120 (1997) F9 Witzenbichler et al, "Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia," Am. J. Pathol. 153(2):381-394 (1998) Wright, et al., "Inhibition of angiogenesis in vitro and in ovo with an inhibitor of cellular protein kinases, MDL 27032," J. Cellular Phys. 152:448-57 (1992) Yarden et al., "Growth factor receptor tyrosine kinases," Ann. Rev. Biochem. 57:443-478 (1988) F12 Zindy et al., "Cyclin A is required in S phase in normal Pepithelial cells," Biochemical & Biophysical Research Communications, 182:1144-1154 (1992) Olofsson et al., "Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells," PNAS USA 95:11709-11714 (1998) Examiner **Date Considered** /Rei Tsang Shiao/ (05/15/2006) EXAMINER: Initial if reference considered, whether or not citation is In conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

•					_	_
	APPLICANT	FACSIMILE	OF 1	FORM	PTO-14	48

REV 7-80

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

BBI-6077CP

09/777,554

LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)

Cusack, K. P. et al.

February 8, 2001

GROUP 1626

U.S. PATENT DOCUMENTS

B	MINER ITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
R	ls.	A1	4,966,849	10/90	Vallee et al.	435	199	IF APPROPRIATE	
R	s	A2	5,217,999	06/93	Levitzki et al.	514	613		
R	S	A3	5,302,606	04/94	Spada et al.	514	357		
RS		A4	5,330,992	07/94	Eissenstat et al.	514	312		
	-						L		

FOREIGN PATENT DOCUMENTS

			OCCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	ATION
R	s	A5	WO 91/15495 A1	10/91	PCT	 		YES	NO
	ī	A6	WO 92/20642 A1	11/92	PCT	-		 	├
		A7	WO 92/21660 A1	12/92	PCT			 	├
		A8	WO 94/03427 A1	02/94	PCT				├
		A9	WO 94/10202 A1	05/94	PCT	 			—
		A10	WO 94/14808 A1	07/94	PCT	+			<u> </u>
		A11	EP 566 226 B1	11/95	EPO				
		A12	WO 97/22596 A1	06/97	PCT				
	Γ	A13	WO 97/34876 A1	09/97	PCT				
		A14	WO97/40830 A1	11/97	PCT	 			
	Γ	A15	WO 97/40831 A1	11/97	PCT				
	/	A16	WO 97/42187 A1	11/97	PCT	 			<u> </u>
	RS	A17	WO 98/07832 A1	02/98	PCT				<u> </u>

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	RS	A18	Expert Opin. Ther. Pat. 8(4): 475-478 (1998)	
		A19	Achen et al, "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," PNAS USA 95(2): 548-553 (1998)	
		A20	Aplin et al., "In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta," <i>Journal of Neurochemistry</i> , 67:699-707 (1996)	
Armstrong, "Treatment of opportunistic fungal infections," Clinical Infectious Diseating (1993)				
\	RS	A22	Badger et al., "Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function," The Journal of Pharmacology and Experimental Therapeutics, 279:1453-1461 (1996)	
E	kamii	ner	Date Considered /Rei Tsang Shiao/ (05/15/2006)	
•€	*EXAMINER:		Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

			Sheet 2 of 6
APPLICANT FACSIMILE OF FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO	SERIAL NO.
REV 7-80	PATENT AND TRADEMARK OFFICE	BBI-6077CP	09/777,554
LIST OF PUBLICATIONS C	ITED BY APPLICANT	APPLICANT	
(Use several sheets	if necessary)	Cusack, K. P. et al.	
403		FILING DATE	GRQU-626

February 8, 2001 OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) Baeuerle et al., "Function and activation of NF-kappa B in the immune system," Annual Review of Immunology, 12:141-179 (1994) Beq et al., "An essential role for NF-kappaB in preventing TNF-alpha-induced cell death," Science, 274:782-784 (1996) ŔΊ Bolen, "Nonreceptor tyrosine protein kinases," Oncogene 8:2025-2031 (1993) R4 Borthwick et al., "Inhibition of glycogen synthase kinase-3 by insulin in cultured human skeletal muscle myoblasts, Biochemical & Biophysical Research Communications, 210:738-745 (1995) **B5** Brickell, "The p60c-src family of protein-tyrosine kinases: structure, regulation, and function." Critical Reviews in Oncogenesis, 3:401-406 (1992) ₿6 Brown et al., Regulation of Angiogenesis (ed. L.D. Goldberg and E.M. Rosen), 233-269 (1997) **B7** Buchdunger et al., "Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class," PNAS USA, 92:2258-2262 (1995) **B8** Courtneidge, "Protein tyrosine kinases, with emphasis on the Src family," Seminars in Cancer Biology, 5:236-246 (1994) Cowburn, "Peptide recognition by PTB and PDZ domains," Curr. Opin. Struct. Biol, 7(6):835-838 89 B10 De Vries et al. "The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor," Science 255:989-991 (1992) B11 Draetta, "Cdc2 activation: The interplay of cyclin binding and Thr161 phosphorylation," Trends in Cell Biology, 3:287-289 (1993) **B12** Ducommun et al., "cdc2 phosphorylation is required for its interaction with cyclin," EMBO Journal, 10:3311-3319 (1991) Fantl et al., "Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that **B13** mediate different signaling pathways," Cell 69:413-423 (1992) Ferrara et al. "The vascular endothelial growth factor family of polypeptides," J. Cell. Biochem. 47:211-218 (1991) B15 Ferrara et al., "Vascular endothelial growth factor. Basic biology and clinical implications," in Regulation of Angiogenesis (ed. L. D. Goldberg and E.M. Rosen), 209-232 (1997) B16 Ferrara et al., "The biology of vascular endothelial growth factor," Endocrine Reviews 18(1): 4-25 Gautier et al., "Dephosphorylation and activation of Xenopus p34cdc2 protein kinase during the cell cycle," Nature 339:626-629 (1989) **B18** Gilbert, "Horizontal integration and cortical dynamics," Neuron 9:1-13 (1992) Girard et al., "Cyclin A is required for the onset of DNA replication in mammalian fibroblasts," Cell, **B19** 67:1169-1179 (1991) Examiner Date Considered /Rei Tsang Shiab/ (05/15/2006)

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT	FACSIMILE	OF	FORM PTO-1449

U.S. DEPARTMENT OF

ATTY DOCKET NO	SERIAL NO.
BBI-6077CP	09/777,554
APPUCANT	

LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)

GROUP1626 February 8, 2001

100	February 8, 2001
5 500g R	OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)
5 2006 PA	Gould et al., "Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates into mitosis," Nature, 342:39-45 (1989)
C2	He et al., "The human cytomegalovirus UL97 protein is a protein kinase that autophosphor on serines and threonines," <i>Journal of Virology</i> , 71:405-411 (1997)
C3	Hosoi et al., "Evidence for cdk5 as a major activity phosphorylating tau protein in porcine be extract," Journal of Biochemistry (Tokyo), 117:741-749 (1995)
C4	Hunter et al., "Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age," Cell, 79:5 (1994)
C5	Jakeman et al., "Developmental expression of binding sites and messenger ribonucleic aci vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis," Endocrinology 133: 848-859 (1993)
. C6	Jellinek, et al., "Inhibition of receptor binding by high-affinity RNA ligands to vascular endot growth factor," <i>Biochemistry</i> 33:10450-56 (1994)
C7	Kendall et al., "Inhibition of vascular endothelial cell growth factor activity by an endogenou encoded soluble receptor," Proc. Natl. Acad. Sci 90:10705-09 (1994)
C8	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresse tumour growth in vivo," Nature 362:841-844 (1993)
C9	Kinsella, et al. "Protein kinase C regulates endothelial cell tube formation on basement membrane matrix, Matrigel," Exp. Cell Res. 199:56-62 (1992)
C10	Klagsburn et al., "Vascular endothelial growth factor and its receptors," Cytokine & Growth Reviews 7: 259-270 (1996)
C11	Koch et al., "SH2 and SH3 domains: elements that control interactions of cytoplasmic signal proteins," Science 252:668-678 (1991)
C12	Kohn et al., "Cell cycle control and cancer chemotherapy," Journal of Cellular Biochemistry 54:440-452 (1994)
C13	Kolch et al., "Regulation of the expression of the VEGF/VPS and its receptors: role in tumo angiogenesis," Breast Cancer Research and Treatment 36: 139-155 (1995)
C14	Korpelainen et al., "Signaling angiogenesis and lymphangiogenesis," Curr. Opin. Cell Biol., 10:159-164 (1998)
C15	Krek et al., 'Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in cells: evidence for a double block to p34cdc2 kinase activation in vertebrates," EMBO Journ 10:3331-3341 (1991)
C16	Lees, "Cyclin dependent kinase regulation," Current Opinion in Cell Biology, 7:773-780 (199
C17	Lymboussaki et al, "Expression of the vascular endothelial growth factor C receptor VEGFF lymphatic endothelium of the skin and in vascular tumors," Am. J. Pathol. 153(2): 395-403 (
C18	Maglione et al. "Two alternative mRNAs coding for the angiogenic factor, placenta growth factor growth growth factor growth factor growth factor growth factor growth growth factor growth growth growth growth growth growth growth g
C19	Mariani, et al., "inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," Am. Assoc. Cancer Res. 35:2268 (1994)
RS C20	Matsushime et al., "D-type cyclin-dependent kinase activity in mammalian cells," Molecular Cellular Biology, 14:2066-2076 (1994)
Examiner	Date Considered /Rei Tsang Shiao/ (05/15/2006)
*EXAMINE	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line throug citation if not in conformance and not considered. Include copy of this form with next communication to a

	APPLICATION OF THE PROPERTY OF			Sheet 4 of 6	
	APPLICANT FACSIMILE OF FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO	SERIAL NO.	_
	REV 7-80	PATENT AND TRADEMARK OFFICE	BBI-6077CP	09/777,554	
	LIST OF PUBLICATIONS CI	TED BY APPLICANT	APPUCANT		-
	(Use several sheets	if necessary)	Cusack, K. P. et al.		
,	40		FILING DATE	GROU ¹ 1626	-

February 6, 2001 OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) Matthews et al., "A receptor tyrosine kinase cDNA isolated from a population of enriched primitive. hematopoietic cells and exhibiting close genetic linkage to c-kit," PNAS USA, 88:9026-30 (1991) Meyer et al, "A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates D2 angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases," EMBO J. 18(2):363-374 (1999) Migdal et al, "Neuropilin-1 is a placenta growth factor-2 receptor," J. Biol. Chem. 273 (35): 22272-**D3** 22278 (1998) Millauer et al., "High affinity VEGF binding and developmental expression suggest Flk-1 as a **D4** major regulator of vasculogenesis and angiogenesis," Cell 72:835-846 (1993) Murray et al., "Cyclin synthesis drives the early embryonic cell cycle," Nature, 339:275-280 (1989) D5 06 Mustonen et al., "Endothelial receptor tyrosine kinases involved in angiogenesis," J. Cell Biol. 129:895-898 (1995) **D**7 Myers et al., "The preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)quinazolines: inhibitors of p56th and EGF-R tyrosine kinase activity," Bioorg. Med. Chem. Lett. 7:417-420 (1997) Myers et al., "The synthesis and sar of new 4-(N-alkyl-N-phenyl)amino-6,7dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)amino-pyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity," Bioorganic & Medicinal Chemistry Letters, 7:421-424 (1997) D9 Oelrichs et al, "NYK/FLK-1: a putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo," Oncogene 8(1):11-15 (1993) Ogawa et al, "A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), D10 preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparinbindir g domain," J. Biol. Chem. 273(47): 31273-31282 (1998) 011 Ohtsubo et al., "Cyclin-dependent regulation of G1 in mammalian fibroblasts," Science, 259:1908-1912 (1993) D12 Osmani et al., "Parallel activation of the NIMA and p34cdc2 cell cycle-regulated protein kinases is required to initiate mitosis in A. nidulans, Cell, 67:283-291 (1991) D13 Osmani et al., "Activation of the nimA protein kinase plays a unique role during mitosis that cannot be bypassed by absence of the bimE checkpoint," EMBO Journal, 10:2669-2679 (1991) Pagano et al., "Cyclin A is required at two points in the human cell cycle," EMBO Journal, 11:961-D15 Park et al., "Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR." J. Biol. Chem. 269:25646-54 (1994) D16 Perkins et al., "Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator," Science, 275:523-527 (1997) Examiner Date Considered /Rei Tsang Shiao (05/15/2006) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

				Sheet 5 of 6
	APPLICANT FACSIMILE OF FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO	SERIAL NO.
	REV 7-80	PATENT AND TRADEMARK OFFICE	BBI-6077CP ()	09/777,554
	LIST OF PUBLICATION	S CITED BY APPLICANT	APPLICANT	
	(Use several sh	eets if necessary)	Cusack, K. P. et al.	
Ì	1	**	FILING DATE	GROUP1626

February 8, 2001

5 [000				OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)						
	Ref	\$	/E1	Pines, "Cell proliferation and control," Current Opinion in Cell Biology, 4:144-148 (1992)						
			E2	Pines, "Cyclins and cyclin-dependent kinases: take your partners," <i>Trends in Biochemical Sciences</i> , 18:195-197 (1993)						
			E3	Powis, "Signalling pathways as targets for anticancer drug development," Pharmacology & Therapeutics, 62:57-95 (1994)						
			E4	Quelle et al., "Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts," Genes & Development, 7:1559-1571 (1993)						
			E5	Resnitzky et al., "Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system," Molecular & Cellular Biology, 14:1669-1679 (1994)						
			E6	Ristimaki et al, "Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C," J. Biol. Chem. 273(14):8413-8418 (1998)						
			E7	Rosenblatt et al., "Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A," Proc. Nat Acad. Sc. USA, 89:2824-2828 (1992)						
			E8	Schlessinger et al., "Growth factor signaling by receptor tyrosine kinases," Neuron 9:383-391 (1992)						
			E9	Shawver et al., "Receptor tyrosine kinases as targets for inhibition of angiogenesis," <i>Drug Discovery Today</i> , 2:50-63 (1997)						
			E10	Sherr, "Mammalian G1 cyclins," Cell, 73:1059-1065 (1993)						
			E11	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely related to the fms family," Oncogene 5:519-524 (1990)						
			E12	Shoelson, "SH2 and PTB domain interactions in tyrosine kinase signal transduction," Curr. Opin. Chem. Biol. 1(2): 227-234 (1997)						
l			E13	Solomon et al., "Cyclin activation of p34cdc2," Cell, 63:1013-1024 (1990)						
			E14	Solomon et al., "Role of phosphorylation in p34cdc2 activation: identification of an activating kinase," Molecular Biology of the Cell, 3:13-27 (1992)						
			E15	Songyang et al., "SH2 domains recognize specific phosphopeptide sequences," Cell 72:767-778 (1993)						
	_		E16	Songyang et al., "Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav," Mol. Cell. Biol. 14:2777-2785 (1994)						
			E17	Staunton et al., "The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and Rhinovirus," Cell 61:243-254 (1990)						
			E18	Stone et al., "Reversible, p16-mediated cell cycle arrest as protection from chemotherapy," Cancer Research, 56:3199-3202 (1996)						
			E19	Takano, et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase," Mol. Bio. Cell 4:358A (1993)						
	R	s	E20	Tanaka et al., "c-CBL is downstream of c-Src in a signalling pathway necessary for bone resorption," Nature, 383:528-531 (1996)						
	Ex	am	iner	Date Considered /Rei Tsang Shiao/ (05/15/2006)						
Ì	• =	VA.	MINICO	Initial if reference considered whether are not visited in the AMPTH and						

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

3	he	et	۶,	٦f	e

_				0,,,,,,	
1	PPUCANT FACSIMILE OF FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO	SERIAL NO.	
1	REV 7-80	PATENT AND TRADEMARK OFFICE	BBI-6077CP	09/777,554	
Ì	LISTOF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT .		
			Cusack, K. P. et al.		
	/ %	•	FILING DATE	1626	
L	MAY 0.5 2006)		February 8, 2001	1020	
_	· · · · · · · · · · · · · · · · · · ·				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) rman et al., "Identification of a new endothelial cell growth factor receptor tyrosine kinase," RS Oncogene 6:1677-83 (1991) F2 Terman et al., "Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor," Biochem. Biophys. Res. Comm. 187:1579-86 (1992) F3 Ullrich et al., "Signal transduction by receptors with tyrosine kinase activity," Cell 61:203-212 F4 Van Antwerp et al., "Suppression of TNF-alpha-induced apoptosis by NF-kappaB," Science. 274:787-789 (1996) F5 Vousden, "Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes," FASEB Journal, 7:872-879 (1993) Walker et al., "Role for cyclin A in the dependence of mitosis on completion of DNA replication," F6 Nature, 354:314-317 (1991) F7 Wang et al., "TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NFkappaB," Science, 274:784-787 (1996) F8 Williams, "Factors regulating the expression of vascular permeability/vascular endothelial growth factor by human vascular tissues," Diabetelogia 40: S118-120 (1997) F9 Witzenbichler et al, "Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia," Am. J. Pathol. 153(2):381-394 (1998) F10 Wright, et al., "Inhibition of angiogenesis in vitro and in ovo with an inhibitor of cellular protein kinases, MDL 27032," J. Cellular Phys. 152:448-57 (1992) F11 Yarden et al., "Growth factor receptor tyrosine kinases," Ann. Rev. Biochem. 57:443-478 (1988) Zindy et al., "Cyclin A is required in S phase in normal Pepithelial cells," Biochemical & Biophysical Research Communications, 182:1144-1154 (1992) Olofsson et al., "Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells," PNAS USA 95:11709-11714 (1998) Examiner Date Considered /Rei Tsang Shiao/ (05/15/2006)

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.